Nova Satra Dx Pte. Ltd. (Nova Satra), a Singapore-based molecular diagnostics startup, has secured $2 million (S$2.8 million) in funding from Genting Bio Cellular Sdn Bhd, a wholly-owned subsidiary of Genting Berhad.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
